On November 9, 2020 Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, reported two upcoming poster presentations at the 35th Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, to be held November 9-14, 2020 (Press release, Apexigen, NOV 9, 2020, View Source [SID1234590992]). Details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title of Presentation: APX601, A Novel TNFR2 Antagonist Antibody for Cancer Immunotherapy (Abstract ID 693)

AUTHORS: Erin L. Filbert, Sushma Krishnan, Ryan Alvarado, George Huang, Frances R. Bahjat, and Xiaodong Yang

PRESENTER: Erin L. Filbert, Ph.D.

The presenting author will answer questions on Wednesday, November 11 from 5:15 to 5:45 p.m. EST and Friday, November13 from 4:40 to 5:10 p.m. EST.

Title of Presentation: Novel Anti-SIRP-α Antibodies with Differentiated Characteristics as Promising Cancer Therapeutics (Abstract ID 188)

AUTHORS: Minu K. Srivastava, Ryan Alvarado, Sushma Krishnan, Christine Tan, Swati Jalgaonkar, George Huang, Erin L. Filbert, Frances R. Bahjat and Xiaodong Yang

PRESENTER: Erin L. Filbert, Ph.D.

The presenting author will answer questions on Thursday, November 12 from 4:50 to 5:20 p.m. EST and Saturday, November 14 from 1:00 to 1:30 p.m. EST.

The posters will be available in the Virtual Poster Hall on November 11-14, 2020, from 9:00 a.m.-5:00 p.m. EST.